Twitxy Saved

Lisa McCabe

@LAHMCCABE

Writing & Reading in Nova Scotia. Member, Board of Directors, Bladder Cancer Canada. UTUC patient. Patient rep, CBC Information System, ICHOM, BC patient rep
Chester, Nova Scotia Joined October 2014
1.4K Following 1.4K Followers 7.5K Posts

Latest posts 5

Lisa McCabe @LAHMCCABE
Much applause and appreciation from this UTUC patient! 👏🏻
Our paper IMPACT UTUC is now published in @NatRevUrol: an international multidisciplinary Delphi consensus on #UTUC
doi.org/10.1038/s41585…

@ricautor @RobertoContieri @LauraBukavinaMD @urodocash @PGrivasMDPhD @montypal @sonpavde @AndreaNecchi @jteoh_hk @carme_mir1
View quoted post on X
Lisa McCabe @LAHMCCABE
It is actually really really hard for some patients to report for a myriad of reasons— wanting to appear strong and stoic, not wanting to be seen as a ‘complainer’, the fear that adjusting or curtailing treatment may mean the cancer will return, not wanting to disappoint their loved ones and medical team. The whole culture around cancer heroics feeds into this. Every patient needs to feel and understand that reporting is not a reflection on their character, nor is it giving up.
OncoDaily Verified account @oncodaily Nov 3
“Don't ignore side effects. Report them.”

This is the message of #MedSafetyWeek 2026 (November 2–8), a global campaign supported by the @WHO, highlighting the importance of recognizing and reporting suspected adverse drug reactions.

In oncology, this message is particularly important. Cancer treatments can cause a wide range of side effects, and knowing when to seek medical attention can make a critical difference in patient safety.

Marking MedSafetyWeek 2026, OncoDaily takes a closer look at cancer treatment side effects, warning signs that should never be ignored, and the importance of timely reporting.
@UMCGlobalSafety

Read more: oncodaily.com/oncolibrary/ca…
View quoted post on X
Lisa McCabe @LAHMCCABE
Promising news for LG UTUC! And what of the HG patient with disease in their remaining kidney — Down the road, could this treatment potentially be a kidney-sparing option for select HG patients? Perhaps a naive question— but a question and a worry that keeps UTUC patients up at night.
UroGen Pharma @UroGenPharma Oct 28
New five-year follow-up data from the Olympus study reinforce the long-term durability of response among adults with low-grade upper tract urothelial cancer (LG-UTUC) who achieved a complete response. Learn more about the final results: investors.urogen.com/news-releases/…
View quoted post on X